skip to content »

Translational Biology & Molecular Medicine

Houston, Texas

Benchtop, Research, Bedside and Application
Translational Biology & Molecular Medicine Graduate Program
not shown on screen

Mandeep Bajaj, M.D.

Mandeep Bajaj, M.D.Associate Professor
Department of Medicine - Diabetes, Endocrinology and Metabolism

Phone: 713-798-1712
Fax: 713-798-5214


  • M.D., All India Institute of Medical Sciences, New Delhi, India
  • Residency, Internal Medicine, Montefiore Medical Center, Bronx, NY
  • Fellowship, Endocrinology and Metabolism, Joslin Diabetes Center, Boston, MA
  • Fellowship, Endocrinology, Harvard Medical School - Beth Israel Hospital, Boston, MA

Research Interests

  • Type 2 diabetes and insulin resistance – pathophysiology
  • Effect of FFA on hepatic and peripheral (muscle) insulin resistance and skeletal muscle insulin signaling
  • Vascular and inflammatory effects of adipocytokines
  • Molecular mechanisms of adiponectin action
  • Relationship between hepatic/intramyocellular fat content and insulin action

Clinical Focus

  • Diabetes
  • Endocrinology
  • Cholesterol and other lipid disorders
  • Obesity and thyroid disease

Selected Publications

  • Samson SL, Gonzalez EV, Yechoor V, Bajaj M, Oka K, Chan L. Gene therapy for diabetes: metabolic effects of helper-dependent adenoviral exendin 4 expression in a diet-induced obesity mouse model. Mol Ther. 2008. 16(11):1805-12.
  • Bajaj M, Medina-Navarro R, Suraamornkul S, Meyer C, DeFronzo RA, Mandarino LJ. Paradoxical changes in muscle gene expression in insulin-resistant subjects after sustained reduction in plasma free fatty acid concentration. Diabetes. 2007. 56(3):743-52.
  • Bajaj M, Suraamornkul S, Hardies LJ, Glass L, Musi N, DeFronzo RA. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. Diabetologia. 2007. 50(8):1723-31.
  • Cusi K, Kashyap S, Gastaldelli A, Bajaj M, Cersosimo E. Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes. Am J Physiol Endocrinol Metab. 2007. 292(6):E1775-81.
  • Petersen JR, Finley JB, Okorodudu AO, Mohammad AA, Grady JJ, Bajaj M. Effect of point-of-care on maintenance of glycemic control as measured by A1C. Diabetes Care. 2007. 30(3):713-5.
  • Bajaj M, Ben-Yehuda O. A big fat wedding: association of adiponectin with coronary vascular lesions. J Am Coll Cardiol. 2006. 48(6):1163-5.
  • Briones M, Bajaj M. Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus. Expert Opin Pharmacother. 2006. 7(8):1055-64.

E-mail this page to a friend